» Articles » PMID: 34015061

DC/L-SIGN Recognition of Spike Glycoprotein Promotes SARS-CoV-2 Trans-infection and Can Be Inhibited by a Glycomimetic Antagonist

Overview
Journal PLoS Pathog
Specialty Microbiology
Date 2021 May 20
PMID 34015061
Citations 100
Authors
Affiliations
Soon will be listed here.
Abstract

The efficient spread of SARS-CoV-2 resulted in a unique pandemic in modern history. Despite early identification of ACE2 as the receptor for viral spike protein, much remains to be understood about the molecular events behind viral dissemination. We evaluated the contribution of C-type lectin receptors (CLRS) of antigen-presenting cells, widely present in respiratory mucosa and lung tissue. DC-SIGN, L-SIGN, Langerin and MGL bind to diverse glycans of the spike using multiple interaction areas. Using pseudovirus and cells derived from monocytes or T-lymphocytes, we demonstrate that while virus capture by the CLRs examined does not allow direct cell infection, DC/L-SIGN, among these receptors, promote virus transfer to permissive ACE2+ Vero E6 cells. A glycomimetic compound designed against DC-SIGN, enable inhibition of this process. These data have been then confirmed using authentic SARS-CoV-2 virus and human respiratory cell lines. Thus, we described a mechanism potentiating viral spreading of infection.

Citing Articles

Autoantibodies in hospitalised patients with COVID-19.

Tiniakou E, Casciola-Rosen L, Thomas M, Manabe Y, Antar A, Damarla M Clin Transl Immunology. 2024; 13(12):e70019.

PMID: 39734590 PMC: 11671454. DOI: 10.1002/cti2.70019.


Structural proteins of human coronaviruses: what makes them different?.

Minigulov N, Boranbayev K, Bekbossynova A, Gadilgereyeva B, Filchakova O Front Cell Infect Microbiol. 2024; 14:1458383.

PMID: 39711780 PMC: 11659265. DOI: 10.3389/fcimb.2024.1458383.


MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular....

Perez P, Astorgano D, Albericio G, Flores S, Sanchez-Corzo C, Noriega M Front Immunol. 2024; 15:1420304.

PMID: 39267752 PMC: 11390564. DOI: 10.3389/fimmu.2024.1420304.


Unprecedented selectivity for homologous lectin targets: differential targeting of the viral receptors L-SIGN and DC-SIGN.

Delaunay C, Pollastri S, Thepaut M, Cavazzoli G, Belvisi L, Bouchikri C Chem Sci. 2024; .

PMID: 39246372 PMC: 11376147. DOI: 10.1039/d4sc02980a.


Innate Immunity in Protection and Pathogenesis During Coronavirus Infections and COVID-19.

Malireddi R, Sharma B, Kanneganti T Annu Rev Immunol. 2024; 42(1):615-645.

PMID: 38941608 PMC: 11373870. DOI: 10.1146/annurev-immunol-083122-043545.


References
1.
Amanat F, Stadlbauer D, Strohmeier S, Nguyen T, Chromikova V, McMahon M . A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020; 26(7):1033-1036. PMC: 8183627. DOI: 10.1038/s41591-020-0913-5. View

2.
Tortorici M, Walls A, Lang Y, Wang C, Li Z, Koerhuis D . Structural basis for human coronavirus attachment to sialic acid receptors. Nat Struct Mol Biol. 2019; 26(6):481-489. PMC: 6554059. DOI: 10.1038/s41594-019-0233-y. View

3.
Berzi A, Ordanini S, Joosten B, Trabattoni D, Cambi A, Bernardi A . Pseudo-Mannosylated DC-SIGN Ligands as Immunomodulants. Sci Rep. 2016; 6:35373. PMC: 5062166. DOI: 10.1038/srep35373. View

4.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View

5.
Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B . COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther. 2020; 5(1):128. PMC: 7381863. DOI: 10.1038/s41392-020-00243-2. View